Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors: Peters, Solange ^{a, ∗}, Paz-Ares, Luis G. ^b, Reck, Martin ^c, Carbone, David P. ^d, Brahmer, Julie R. ^e, Borghaei, Hossein ^f, Lu, Shun ^g, O’Byrne, Kenneth J. ^h, John, Thomas ⁱ, Ciuleanu, Tudor-Eliade ^j, Schenker, Michael ^k, Bernabe Caro, Reyes ^l, Nishio, Makoto ^m, Cobo, Manuel ⁿ, Lee, Jong-Seok ^o, Zurawski, Bogdan ^p, Pluzanski, Adam ^q, Aoyama, Takekazu ^r, Tschaika, Marina ^s, Devas, Vipul ^t, Grootendorst, Diederik J. ^u, Ramalingam, Suresh S. ^v

Source: In Journal of Thoracic Oncology January 2025 20(1):94-108

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Schenker, Michael, Bordenave, Stephanie, Cobo, Manuel, Juan-Vidal, Oscar, Reinmuth, Niels, Richardet, Eduardo, Felip, Enriqueta, Menezes, Juliana, Cheng, Ying, Mizutani, Hideaki, Zurawski, Bogdan, Alexandru, Aurelia, Carbone, David P., Lu, Shun, John, Thomas, Aoyama, Takekazu, Grootendorst, Diederik J., Hu, Nan, Eccles, Laura J., Paz-Ares, Luis G.

Source: In European Journal of Cancer November 2024 211

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Authors: Hochmair, Maximilian J., Vermaelen, Karim, Mountzios, Giannis, Carcereny, Enric, Dooms, Christophe, Lee, Se-Hoon, Morocz, Eva, Kato, Terufumi, Ciuleanu, Tudor-Eliade, Dy, Grace K., Parente, Barbara, O’Byrne, Kenneth J., Chu, Quincy S., Castro Junior, Gilberto De, Girard, Nicolas, Snyder, Wendy, Tran, Qui, Kormany, William, Houk, Brett, Mehta, Bhakti, Curioni-Fontecedro, Alessandra

Source: In European Journal of Cancer September 2024 208

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Cheng, Ying, Sakai, Hiroshi, Paz-Ares, Luis, Lu, Shun, John, Thomas, Sun, Xiaowu, Moisei, Aniela, Taylor, Fiona, Lawrance, Rachael, Zhang, Xiaoqing, Sylvester, Judi, Yuan, Yong, Blum, Steven I., Penrod, John R., Carbone, David P.

Source: European journal of cancer. 183:174-187

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190699417.0x000001&indx=1&recIds=ETOCvdc_100190699417.0x000001

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Authors: Forde, Patrick M, Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M, Felip, Enriqueta, Broderick, Stephen R, Brahmer, Julie R, Swanson, Scott J, Kerr, Keith, Wang, Changli, Ciuleanu, Tudor–Eliade, Saylors, Gene B, Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke Neng, Liberman, Moishe, Vokes, Everett E, Taube, Janis M, Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y, Girard, Nicolas

Source: Future oncology. 19(8):549-557

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189952085.0x000001&indx=1&recIds=ETOCvdc_100189952085.0x000001

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Authors: Brahmer, Julie R., Lee, Jong-Seok, Ciuleanu, Tudor-Eliade, Bernabe Caro, Reyes, Nishio, Makoto, Urban, Laszlo, Audigier-Valette, Clarisse, Lupinacci, Lorena, Sangha, Randeep, Pluzanski, Adam, Burgers, Jacobus, Mahave, Mauricio, Ahmed, Samreen, Schoenfeld, Adam J., Paz-Ares, Luis G., Reck, Martin, Borghaei, Hossein, O'Byrne, Kenneth J., Gupta, Ravi G., Bushong, Judith, Li, Li, Blum, Steven I., Eccles, Laura J., Ramalingam, Suresh S.

Source: Journal of clinical oncology. 41(6):1200-1212

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183180176.0x000001&indx=1&recIds=ETOCvdc_100183180176.0x000001

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Authors: Aix, Santiago Ponce, Ciuleanu, Tudor Eliade, Navarro, Alejandro, Cousin, Sophie, Bonanno, Laura, Smit, Egbert F, Chiappori, Alberto, Olmedo, Maria Eugenia, Horvath, Ildiko, Grohé, Christian, Farago, Anna F, López-Vilariño, José Antonio, Cullell-Young, Martin, Nieto, Antonio, Vasco, Noelia, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Carcereny, Enric, Roubec, Jaromir, Syrigos, Konstantinos, Lo, Gregory, Barneto, Isidoro, Pope, Anthony, Sánchez, Amparo, Kattan, Joseph, Zarogoulidis, Konstantinos, Waller, Cornelius F, Bischoff, Helge, Juan-Vidal, Oscar, Reinmuth, Niels, Dómine, Manuel, Paz-Ares, Luis

Source: Lancet.Respiratory medicine. 11(1):74-86

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100178078822.0x000001&indx=1&recIds=ETOCvdc_100178078822.0x000001

Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute.

Authors: Preda, Alexandra-Cristina^1,2 (AUTHOR) madalina.prodan06@gmail.com, Ciuleanu, Tudor-Eliade^1,2 (AUTHOR) dadi.varro@gmail.com, Todor, Nicolae¹ (AUTHOR) tdrnicolae@gmail.com, Vlad, Cătălin^1,2 (AUTHOR) catalinvlad@yahoo.it, Iancu, Dana Ioana¹ (AUTHOR) dana_iancu2004@yahoo.com, Mocan, Cristina¹ (AUTHOR) mocan.cristina@gmail.com, Bandi-Vasilica, Mariana¹ (AUTHOR) bandi.vmariana@gmail.com, Albu, Florina¹ (AUTHOR) florinaalbu18@gmail.com, Todor-Bondei, Irina Mihaela¹ (AUTHOR) airina202003@yahoo.com, Hapca, Mădălina Claudia² (AUTHOR), Kubelac, Milan-Paul¹ (AUTHOR) paulkubelac@gmail.com, Kubelac-Varro, Adelina Dadiana² (AUTHOR)

Source: Cancers. Jun2024, Vol. 16 Issue 11, p2022. 26p.

Subject Terms: *THERAPEUTIC use of monoclonal antibodies, *CANCER treatment, *RESEARCH funding, *IMMUNOTHERAPY, *CLINICAL trials, *TREATMENT effectiveness, *CANCER patients, *MULTIVARIATE analysis, *AGE distribution, *DESCRIPTIVE statistics, *ADJUVANT chemotherapy, *COMBINED modality therapy, *DRUG efficacy, *STATISTICS, *LUNG cancer, *NIVOLUMAB, *PROGRESSION-free survival, *SPECIALTY hospitals, *IPILIMUMAB, *OVERALL survival, *EVALUATION

Geographic Terms: ROMANIA

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., Brahmer, Julie R.

Source: In Journal of Thoracic Oncology August 2023 18(8):1055-1069

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Authors: Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., Reck, Martin

Source: In Journal of Thoracic Oncology February 2022 17(2):289-308

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Audigier-Valette, Clarisse, Zurawski, Bogdan, Linardou, Helena, Otterson, Gregory A., Salman, Pamela, Nishio, Makoto, de la Mora Jimenez, Emmanuel, Lesniewski-Kmak, Krysztof, Albert, István, Ahmed, Samreen, Syrigos, Konstantinos, Penrod, John R., Yuan, Yong, Blum, Steven I., Nathan, Faith E., Sun, Xiaowu, Moreno-Koehler, Alejandro, Taylor, Fiona, O'Byrne, Kenneth John

Source: In Journal of Thoracic Oncology April 2021 16(4):665-676

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Authors: Paz-Ares, Luis ^*, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Sakai, Hiroshi, Lingua, Alejo, Salman, Pamela, Souquet, Pierre-Jean, De Marchi, Pedro, Martin, Claudio, Pérol, Maurice, Scherpereel, Arnaud, Lu, Shun, John, Thomas, Carbone, David P, Meadows-Shropshire, Stephanie, Agrawal, Shruti, Oukessou, Abderrahim, Yan, Jinchun, Reck, Martin

Source: In The Lancet Oncology February 2021 22(2):198-211

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Authors: Paz-Ares, Luis G., Pérol, Maurice, Ciuleanu, Tudor-Eliade, Kowalyszyn, Ruben Dario, Reck, Martin, Lewanski, Conrad R., Syrigos, Konstantinos, Arrieta, Oscar, Prabhash, Kumar, Park, Keunchil, Pikiel, Joanna, Göksel, Tuncay, Lee, Pablo, Zimmermann, Anna, Carter, Gebra Cuyun, Alexandris, Ekaterine, Garon, Edward B.

Source: In Lung Cancer October 2017 112:126-133

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Authors: Pérol, Maurice, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N., Goksel, Tuncay, Park, Keunchil, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Lewanski, Conrad R., Thomas, Michael, Dakhil, Shaker, Kim, Joo-Hang, Karaseva, Nina, Yurasov, Sergey, Zimmermann, Annamaria, Lee, Pablo, Carter, Gebra Cuyun, Reck, Martin, Cappuzzo, Federico, Garon, Edward B.

Source: In Lung Cancer March 2016 93:95-103

MicroRNAs expression profile in chemotherapy-induced cardiotoxicity in non-small cell lung cancer using a co-culture model.

Authors: Romitan, Mihai, Zanoaga, Oana, Budisan, Liviuta, Jurj, Ancuta, Raduly, Lajos, Pop, Laura, Ciocan, Cristina, Pirlog, Radu, Braicu, Cornelia, Ciuleanu, Tudor Eliade, Berindan-Neagoe, Ioana

Source: Biomolecules & Biomedicine; 2024, Vol. 24 Issue 1, p125-137, 13p

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Authors: Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Obermannova, Radka, Bodoky, Gyorgy, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Portnoy, David C, Van Cutsem, Eric, Grothey, Axel, Prausová, Jana, Garcia-Alfonso, Pilar, Yamazaki, Kentaro, Clingan, Philip R, Lonardi, Sara, Kim, Tae Won, Simms, Lorinda, Chang, Shao-Chun, Nasroulah, Federico

Source: In The Lancet Oncology May 2015 16(5):499-508

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Authors: Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice

Source: In The Lancet 23-29 August 2014 384(9944):665-673

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Authors: Butts, Charles, Socinski, Mark A, Mitchell, Paul L, Thatcher, Nick, Havel, Libor, Krzakowski, Maciej, Nawrocki, Sergiusz, Ciuleanu, Tudor-Eliade, Bosquée, Lionel, Trigo, José Manuel, Spira, Alexander, Tremblay, Lise, Nyman, Jan, Ramlau, Rodryg, Wickart-Johansson, Gun, Ellis, Peter, Gladkov, Oleg, Pereira, José Rodrigues, Eberhardt, Wilfried Ernst Erich, Helwig, Christoph, Schröder, Andreas, Shepherd, Frances A

Source: In Lancet Oncology January 2014 15(1):59-68

Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective.

Authors: Munteanu, Raluca, Tomuleasa, Ciprian, Iuga, Cristina-Adela, Gulei, Diana, Ciuleanu, Tudor Eliade

Source: Cancers; Nov2023, Vol. 15 Issue 22, p5394, 21p

Subject Terms: TREATMENT of lung tumors, DNA, ONCOGENES, LUNG tumors, CANCER patients, TREATMENT effectiveness, GENE expression, METHYLATION, HISTONES, QUALITY of life, EPIGENOMICS

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Authors: Al-Samkari, Hanny, Geredeli, Caglayan ^*, Arslan, Cagatay ^*, Korantzis, Ippokratis ^*, Dogu, Gamze Gokoz ^*, Nechaeva, Marina ^*, Fernandez, Mercedes Salgado ^*, Astorga, Beatriz Gonzalez ^*, Yordanov, Valeriy ^*, Ciuleanu, Tudor-eliade ^*, Bowers, Charles, Armas, Armando ^*, Scotte, Florian ^*, Camargo, Johnny ^*, Muñoz, César ^*, Bunn, Paul ^*, Kuter, David J., Soff, Gerald A.

Source: In Blood 15 November 2022 140 Supplement 1:11250-11252